Skip to main content


We’d like to understand how you use our websites in order to improve them. Register your interest.

Efficacy and safety of the use of omalizumab in a patient with difficult-to-control severe asthma and antiphospholipid antibody syndrome


Autoimmune conditions may be associated with allergic diseases. There are few studies on the safety of omalizumab use in patients with asthma who also present autoimmune disease.


Case report of a patient with severe asthma associated with antiphospholipid antibody syndrome (APS) treated with omalizumab.


Female, 36-year-old patient, with uncontrolled asthma, dependent on oral corticosteroid. Patient had a history of cough, wheezing and dyspnea since childhood with worsening in the past few years, with dyspnea on minimal activities and use of rescue albuterol 3-10 times a day. She had a history of intensive care unit admission and intubation for asthma on two occasions. Associated conditions were: APS (thrombosis of the leg, miscarriage, stillbirth and positive lupus anti-coagulant, use of aspirin, depression, GERD, and allergic rhinitis. She was on Formoterol/Budesonide 12/400mcg plus inhaled Beclomethasone 800mcg twice daily; Montelukast 10mg a day; Prednisone 5mg daily; Fluoxetine 40mg daily; nasal Budesonide 50mcg twice a day; Omeprazole 20mg once a day.

Her initial spirometry showed an FEV1 of 47% predicted, with response to bronchodilator (21% and 300mL reversibility). This pattern remained throughout her follow up in our Clinic. Her total IgE was 120kU/L, and she presented positive skin prick tests to Dermatophagoides pteronyssinus, D. farinae and Trichophyton and negative to Aspergillus. Chest tomography and bronchoscopy were unremarkable.

Despite correct use of medications, the patient had frequent exacerbations and need for increasing doses of oral prednisone up to 80mg daily, with weight gain of 18kg in 3 years. Omalizumab was started, and within two weeks the patient showed marked improvement of symptoms, making it possible to withdraw prednisone. There was reduction in use of rescue albuterol, improvement in quality of life and weight loss. After 9 months, treatment with omalizumab was discontinued due to supply problems, with worsening of asthma and return of oral corticosteroids. Provision of omalizumab was restored after 6 months, and the patient again had improvement of symptoms and discontinuation of oral corticosteroids. Currently, she uses rescue bronchodilator 2 times a week, lost 20kg and practices physical activity.


Omalizumab was very effective in controlling symptoms in a patient with severe asthma and APS. No adverse effects related to medication use were observed.


Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Author information



Corresponding author

Correspondence to Rosangela Villela.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Villela, R., Melo, J.M., Nociti, T. et al. Efficacy and safety of the use of omalizumab in a patient with difficult-to-control severe asthma and antiphospholipid antibody syndrome. World Allergy Organ J 8, A219–A220 (2015).

Download citation